Scientists at ETH Zurich say they have developed a technique for concentrating and releasing drugs in the brain with much accuracy. This could make it possible in the future to deliver psychiatric and cancer drugs and other medications only to those regions of the brain where this is medically desirable, according to the team.
Results identify intestinal epithelial 5-HT as a new and potentially safer therapeutic target for mood regulation.
Metabolic changes influence T cell identity and open avenues for interventions to sustain immune function.
Gene editing technology is being widely deployed to generate precise data about disease-causing gene mutations and networks, helping to identify optimal therapeutic targets. These approaches…
Previous studies found that genes inherited from Neanderthals may contribute to greater pain sensitivity and impact the shape of our noses.
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma. In this GEN…
Results identify intestinal epithelial 5-HT as a new and potentially safer therapeutic target for mood regulation.
The risk of a wrong product being dosed to a patient is exacerbated by a lack of standardization within the cell and gene therapy industry.
By monitoring critical metabolic parameters, a path can be mapped out to create golden batches, which meet or exceed all of the critical process parameters.
Bioprocessing technology has a role to play in helping developers exert greater control over production processes.
By doing early screening, it’s possible for researchers to accelerate process development and move to commercial bsAb manufacturing.
